What do patients want from their treatment?

Patients’ expectations of treatment for major depressive disorder (MDD) differ, so the treatment goals need to be meaningful for each individual patient. Such individualized goals can be determined and managed appropriately using a patient-centered, shared decision-making approach and a goal attainment scale to establish and track progress, explained experts at WPA 2021.

MDD is the leading cause of disability worldwide with high morbidity and mortality,1 said Professor Siegfried Kasper, Medical University of Vienna, Austria. Initiation of treatment is therefore of utmost importance, but which treatment?

Patients’ expectations of treatment differ

 

Relationship between symptoms and function

Professor Dan Stein, University of Cape Town, South Africa highlighted the heterogeneity of MDD. Each patient has their own unique combination of symptoms,2 resulting in differing effects on personal, social, and work function.

Patients’ expectations of their treatment therefore differ, and treatment needs to be tailored to the patient, he said.

Each patient has a unique experience of MDD

Professor Sidney Kennedy, University of Toronto, Canada described how different symptoms affect a patient’s ability to function:

  • Overall, sad mood, concentration problems, fatigue, and loss of interest have most impact on psychosocial function3
  • Low energy is experienced by 91% of patients and is more predictive of poorer work and social functioning than other depressive symptoms, and improvement in energy is more strongly related to improved work productivity4
  • Improving motivation predicts early improvement and has the best predictive value for response5

 

Treatment goals

The most important goals are positive mental health and a return to one's usual self and life

Patients and doctors need to have the same treatment goals, said Professor Kasper, and this is best achieved by shared decision making.

A patient-centered approach using a goal attainment scale to establish and track progress toward treatment goals that are meaningful to patients has been advocated.6

Professor Kasper noted that for the majority of patients who have set such goals, the goals concern:

  • physical health
  • cognitive functioning
  • social aspects of life7 

The most important goals are positive mental health (e.g. optimism and self-confidence) and a return to one's usual self and level of functioning,8 he said.

In addition, it is important to note that a patient’s preference for a particular treatment is a potent moderator of response to the treatment.9

 

Which antidepressant?

Antidepressants differ in efficacy and acceptability

All antidepressants are more effective than placebo in the treatment of MDD, but differences in efficacy and acceptability between different antidepressants have been demonstrated in head-to head-trials,10 said Professor Stein.

These were the findings of a systematic review and network meta-analysis by Cipriani et al. published in The Lancet in 2018.

Cipriani et al. concluded that their results should serve evidence-based practice and inform patients, physicians, guideline developers, and policy makers in their decision-making on the use of different antidepressants.10

 

Support for this satellite symposium at WPA 2021 was provided by Servier

 

For the latest updates on sea.progress.im, subscribe to our Telegram Channel https://bit.ly/telePiM

Our correspondent’s highlights from the symposium are meant as a fair representation of the scientific content presented. The views and opinions expressed on this page do not necessarily reflect those of Lundbeck.

References
  1. World Federation for Mental Health. Depression: A Global Crisis. 10 October 2012. Available at https://www.who.int/mental_health/management/depression/wfmh_paper_depression_wmhd_2012.pdf Accessed 12 Mar 21.
  2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). American Psychiatric Publishing 2013.
  3. Fried EI, Nesse RM. PLoS One. 2014;9:e90311.
  4. Swindle R, et al. Energy and improved workplace productivity in depression. In: Farquhar I, et al. Investing in Health: The Social and Economic Benefits of Health Care Innovation (Research in Human Capital and Development, Vol. 14), Emerald Group Publishing Limited, Bingley, pp. 323–41. Available at https://doi.org/10.1016/S0194-3960(01)14013-8. Accessed 14 Mar 21.
  5. Gorwood P, et al. Neuropsychiatr Dis Treat. 2015;11:2875–82.
  6. Barry MJ, Edgman-Levitan S. N Engl J Med 2012;366:780–1.
  7. McNaughton EC, et al. Patient Prefer Adherence. 2019;13:959–67.
  8. Zimmerman M, et al. Am J Psychiatry. 2006;163:148–50.
  9. Kocsis JH, et al. J Clin Psychiatry. 2009;70:354–61.
  10. Cipriani A, et al. Lancet. 2018;391:1357–66.
You are leaving Progress in Mind
Hello
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
The information on this site is exclusively intented for health care professionals.
All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.
Congress
Register for access to Progress in Mind in your country